The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Share News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,898.00
Bid: 1,898.00
Ask: 1,902.00
Change: 6.00 (0.32%)
Spread: 4.00 (0.211%)
Open: 1,852.00
High: 1,908.00
Low: 1,852.00
Prev. Close: 1,892.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Genus shares plunge as expects adjusted profit and revenue decline

Thu, 15th Feb 2024 09:41

(Alliance News) - Genus PLC on Thursday warned that Chinese porcine markets continued to be "challenging", as it anticipates reporting lower revenue and adjusted pretax profit for its recent half-year.

Shares in the Basingstoke, England based animal genetics biotechnology company focused on cattle and pig farms plunged 30% to 1,478.00 pence each on Thursday morning in London.

Genus expects to report adjusted pretax profit for the financial first-half ended December 31 of GBP29 million on revenue of GBP334 million.

Both outcomes will be in line with expectations, but they would represent a 31% slump in adjusted pretax profit from GBP42.2 million a year before and a 4.6% decline on the top line from GBP350.2 million.

"[Pig Improvement Co] ex-China performed robustly, with North America, Latin America and Europe delivering adjusted operating profit growth in constant currency. China continues to be a challenging porcine market, however our enhanced commercial focus has resulted in winning new royalty customers in the period which will positively impact fiscal year 2025 and beyond," Genus added.

PIC sales comprise semen, embryos and breeding animals with 'superior' genetics to those animals currently on farms.

Genus said: "With regards to our PRP programme, recent engagement with the US Food & Drug Administration has shifted to the post-approval compliance procedures. This has clarified the data submissions and monitoring that will be required on an ongoing basis post-PRP approval. Validation of our procedures to comply with these monitoring requirements is expected to take several months. We therefore now expect FDA approval in fiscal year 2025. Our dialogue shifting to the post-approval compliance procedures reinforces our view that approval will be forthcoming. There are no changes to our commercialisation timeline or financial projections."

Genus's PRP programme focuses on pigs who are resistant to porcine reproductive and respiratory syndrome, or PRRS. Genus has developed a solution to protect pigs from the PRRS virus, which causes animal suffering and prematurely kills millions of pigs every year.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
1 Apr 2020 09:33

UK BROKER RATINGS SUMMARY: HSBC Raises M&B, Marston's And Wetherspoon

UK BROKER RATINGS SUMMARY: HSBC Raises M&B, Marston's And Wetherspoon

Read more
26 Mar 2020 16:13

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more
23 Mar 2020 16:58

FTSE 250 movers: Precious metals miners gain, Plus500 jumps

(Sharecast News) - Precious metals miners Hochschild Mining and Petropavlovsk were both wanted at the start of the week, as the US central bank in effect shifted to a policy of unlimited asset purchases, as some analysts had correctly anticipated.

Read more
4 Mar 2020 15:59

FTSE 250 movers: Genus jumps, Restaurant Group slumps

(Sharecast News) - Genus shares hit a fresh record high on the back of an update from sausage skin manufacturer Devro which reported that its factory in Nantong, China, had returned to normal production.

Read more
27 Feb 2020 16:08

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more
27 Feb 2020 11:14

Genus sees strong revenue growth in first half

(Sharecast News) - Animal genetics company Genus reported "strong" revenue growth of 13% in actual and constant currency in its half-year results on Thursday, to ?270.7m.

Read more
27 Feb 2020 10:15

Genus Turns To Interim Profit And Lifts Dividend, Backs Annual Outlook

Genus Turns To Interim Profit And Lifts Dividend, Backs Annual Outlook

Read more
20 Feb 2020 16:05

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
28 Nov 2019 09:41

UK BROKER RATINGS SUMMARY: Morgan Stanley Upgrades Property Investors

UK BROKER RATINGS SUMMARY: Morgan Stanley Upgrades Property Investors

Read more
22 Nov 2019 16:06

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more
20 Nov 2019 08:48

Former Compass Group Finance Executive Henriksen Joins Genus As CFO

Former Compass Group Finance Executive Henriksen Joins Genus As CFO

Read more
20 Nov 2019 08:01

Genus names Alison Henriksen as CFO

(Sharecast News) - Animal genetics business Genus named Alison Henriksen as its next chief financial officer on Wednesday.

Read more
15 Nov 2019 13:09

Friday broker round-up

(Sharecast News) - Whitbread: Barclays upgrades to overweight with a target price of 4,900p.

Read more
15 Nov 2019 09:30

UK BROKER RATINGS SUMMARY: Berkeley Gets Cut; Barclays Likes Whitbread

UK BROKER RATINGS SUMMARY: Berkeley Gets Cut; Barclays Likes Whitbread

Read more
14 Nov 2019 13:10

Thursday broker round-up

(Sharecast News) - Tullow Oil: Jefferies downgrades to hold with a target price of 168p.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.